Quick Answer
BioXcel Therapeutics, Inc. reported Diluted EPS of $5.73 per share (loss) for fiscal year 2025.
BioXcel Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.73 | +75.6% |
| 2024 | -$23.51 | +76.1% |
| 2023 | -$98.33 | -1561.0% |
| 2022 | -$5.92 | -46.2% |
| 2021 | -$4.05 | -6.9% |
| 2020 | -$3.79 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.18 | +57.7% | +11.0% |
| June 30, 2025 | -$2.45 | +25.8% | -63.3% |
| March 31, 2025 | -$1.50 | +89.2% | +70.9% |
| September 30, 2024 | -$5.15 | -199.4% | -56.1% |
| June 30, 2024 | -$3.30 | -80.3% | +76.2% |
| March 31, 2024 | -$13.89 | -654.9% | -707.6% |
| September 30, 2023 | -$1.72 | -15.4% | +6.0% |
| June 30, 2023 | -$1.83 | -35.6% | +0.5% |
- BioXcel Therapeutics, Inc. showed an increase of +75.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, BioXcel Therapeutics, Inc.’s diluted eps has declined by 51.2% (from $3.79 per share (loss) to $5.73 per share (loss)).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: